Editas Medicine (LTS:0IFK) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IFK Editas Medicine Inc LTS:0IFK
52 GF Score
Price $2.84
GF Value $1.78
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine FFO per Share?

FFO per Share only applies to REITs.

LTS:0IFK
52GF Score
Editas Medicine Inc LTS:0IFK
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Editas Medicine (LTS:0IFK) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $2.84 is trading 59.6% above its estimated GF Value™ of $1.78. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for LTS:0IFK:

  • FFO per Share:
  • GF Value™: $1.78 vs. price of $2.84 (59.6% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges EDIT:USA8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
52GF Score

Get the complete analysis for LTS:0IFK

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.84
Price
$1.78
GF Value